Activity of moxifloxacin, imipenem, and ertapenem against Escherichia coli, Enterobacter cloacae, Enterococcus faecalis, and Bacteroides fragilis in monocultures and mixed cultures in an in vitro pharmacokinetic/pharmacodynamic model simulating concentrations in the human pancreas.
The activities of moxifloxacin, imipenem, and ertapenem against pathogens causing severe necrotizing pancreatitis were studied in an in vitro pharmacokinetics/pharmacodynamics (PK/PD) model. Escherichia coli, Enterobacter cloacae, Enterococcus faecalis, and Bacteroides fragilis were exposed in monocultures and mixed cultures to concentrations of the three agents comparable to those in the human pancreas. Moxifloxacin was more active than the two carbapenems in monocultures and mixed cultures, reducing the numbers of CFU more drastically and more rapidly.
Christian-Albrechts University of Kiel, Kiel, Germany.
Sabine
S
Schubert
Axel
A
Dalhoff
D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D001372:Aza Compounds / Q000493:pharmacokinetics / Q000494:pharmacology*; D058491:Bacterial Load; D001441:Bacteroides fragilis / Q000187:drug effects*; D015169:Colony Count, Microbial; D016972:Enterobacter cloacae / Q000187:drug effects*; D013293:Enterococcus faecalis / Q000187:drug effects*; D000077727:Ertapenem; D004926:Escherichia coli / Q000187:drug effects*; D024841:Fluoroquinolones; D006801:Humans; D015378:Imipenem / Q000493:pharmacokinetics / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D015233:Models, Statistical; D000077266:Moxifloxacin; D010179:Pancreas / Q000378:metabolism*; D019283:Pancreatitis, Acute Necrotizing / Q000382:microbiology; D011804:Quinolines / Q000493:pharmacokinetics / Q000494:pharmacology*; D012044:Regression Analysis; D047090:beta-Lactams / Q000493:pharmacokinetics / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D047090:beta-Lactams; D015378:Imipenem; D000077727:Ertapenem; D000077266:Moxifloxacin